156 related articles for article (PubMed ID: 16007877)
1. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
3. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
5. Nodular lymphocyte-predominant Hodgkin's lymphoma.
Nogovà L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
[TBL] [Abstract][Full Text] [Related]
6. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
[TBL] [Abstract][Full Text] [Related]
8. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
9. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.
Bräuninger A; Wacker HH; Rajewsky K; Küppers R; Hansmann ML
Cancer Res; 2003 Apr; 63(7):1644-51. PubMed ID: 12670918
[TBL] [Abstract][Full Text] [Related]
10. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
[TBL] [Abstract][Full Text] [Related]
11. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
[TBL] [Abstract][Full Text] [Related]
12. [Hodgkin lymphoma. Classification and pathogenesis].
Foss HD; Marafioti T; Stein H
Pathologe; 2000 Mar; 21(2):113-23. PubMed ID: 10840817
[TBL] [Abstract][Full Text] [Related]
13. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
[TBL] [Abstract][Full Text] [Related]
14. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
15. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
[TBL] [Abstract][Full Text] [Related]
16. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.
Appel BE; Chen L; Buxton AB; Hutchison RE; Hodgson DC; Ehrlich PF; Constine LS; Schwartz CL
J Clin Oncol; 2016 Jul; 34(20):2372-9. PubMed ID: 27185849
[TBL] [Abstract][Full Text] [Related]
17. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
Müller RP; Eich HT
Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
[TBL] [Abstract][Full Text] [Related]
18. [Treatment results of Hodgkin's lymphoma].
Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
[TBL] [Abstract][Full Text] [Related]
19. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
20. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]